diphosphoric acid tetraisopentyl ester | 648916-71-6

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机含氧阴离子化合物
• 英文名称: diphosphoric acid tetraisopentyl ester
• 英文别名: Diphosphorsaeure-tetraisopentylester；Tetraisopentylpyrophosphat；isopentyl pyrophosphate；Tetrakis(3-methylbutyl) diphosphate；bis(3-methylbutoxy)phosphoryl bis(3-methylbutyl) phosphate
• CAS: 648916-71-6
• 化学式: C₂₀H₄₄O₇P₂
• 分子量: 458.513
• InChiKey: KMIOKWLBZXNRFJ-UHFFFAOYSA-N

物化性质

• 沸点：
  171-172 °C(Press: 0.1 Torr)
• 密度：
  1.041±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  29
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  80.3
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  diisopentyl phosphorochloridate 在 水 、 甲苯 作用下， 生成 diphosphoric acid tetraisopentyl ester
  参考文献：
  名称：

  Process for making tetraalkyl pyrophosphates

  摘要：

  公开号：

  US02479939A1

文献信息

• [EN] BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS<br/>[FR] COMPOSÉS BENZAMIDE OU BENZAMINE À UTILISER EN TANT QU'ANTICANCÉREUX POUR LE TRAITEMENT DE CANCERS HUMAINS
  申请人：UNIV TEXAS

  公开号：WO2017007634A1

  公开（公告）日：2017-01-12

  The described invention provides small molecule anti-cancer compounds for treating tumors that respond to cholesterol biosynthesis inhibition. The compounds selectively inhibit the cholesterol biosynthetic pathway in tumor-derived cancer cells, but do not affect normally dividing cells.

  所描述的发明提供了用于治疗对胆固醇生物合成抑制作出反应的肿瘤的小分子抗癌化合物。这些化合物选择性地抑制肿瘤来源的癌细胞中的胆固醇生物合成途径，但不影响正常分裂的细胞。
• [EN] SURFACTANTS<br/>[FR] TENSIOACTIFS
  申请人：AMYRIS INC

  公开号：WO2012103156A1

  公开（公告）日：2012-08-02

  This application relates to derivatives of hydrocarbon terpenes (e.g., myrcene or farnesene), to methods of making the derivatives, and to the use of the derivatives as surfactants.

  这个应用涉及到碳氢化合物萜类化合物（例如，肉豆蔻烯或芬尼烯）的衍生物，制备这些衍生物的方法，以及将这些衍生物用作表面活性剂的用途。
• Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
  申请人：Griffin John

  公开号：US20050261354A1

  公开（公告）日：2005-11-24

  The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.

  本发明提供了物质组合物、试剂盒和它们在治疗MAP激酶相关疾病和/或HMG-CoA还原酶相关疾病中的应用的方法。具体而言，本发明提供了用于通过抑制p38α MAP激酶和/或HMG-CoA还原酶来治疗动物主体的炎症和/或心血管疾病的组合物，以及提供这些组合物的配方和给药方式。本发明还提供了用于有理设计MAP激酶、HMG-CoA还原酶或两者的抑制剂的方法，用于实施本发明。
• [EN] THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER<br/>[FR] AGENTS THÉRAPEUTIQUES CIBLANT LA POLYPOSE ADÉNOMATEUSE COLIQUE (APC) MUTANTE POUR LE TRAITEMENT DU CANCER
  申请人：UNIV TEXAS

  公开号：WO2020117972A1

  公开（公告）日：2020-06-11

  The present disclosure reports an extensive medicinal chemistry evaluation of a large collection of Truncating APC-Selective Inhibitor (TASIN) compounds. The compounds were evaluated for activity against a series of colon cancer cell lines with and without truncating APC-mutations, as well as in an isogenic cell line pair reporting on the status of APC- dependent selectivity. A number of very potent and selective compounds were identified, including compounds with good metabolic stability and PK properties. The small molecules reported herein thus represent a first-in-class genotype-selective series that specifically target ape mutations present in the vast majority of CRC patients, and therefore serves as a translational platform towards a potential targeted therapy for colon cancer.

  本披露报告了对大量截断APC-选择性抑制剂（TASIN）化合物的广泛药物化学评估。这些化合物针对一系列结肠癌细胞系进行了活性评估，包括具有截断APC突变和不具有截断APC突变的细胞系，以及在报告APC依赖性选择性状况的同源细胞系对。鉴定了一些非常有效和选择性的化合物，包括具有良好代谢稳定性和药代动力学性质的化合物。因此，本文报道的小分子代表了一种首创的基因型选择性系列，专门针对存在于绝大多数结直肠癌患者中的猿类突变，因此可作为一个转化平台，朝着结肠癌的潜在靶向治疗迈进。
• PYRAZOLOPYRIMIDINE ANTIBACTERIAL AGENTS
  申请人：BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY

  公开号：US20170355700A1

  公开（公告）日：2017-12-14

  Pyrazolopyrimidine compounds for inhibition of isoprenoid biosynthesis have a formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), R 1 includes an alkyl group and R 2 includes an optionally substituted moiety selected from the group consisting of an optionally substituted benzyl group, an optionally substituted phenethyl group, an optionally substituted ethanol group, an optionally substituted ethyl acetate group, an optionally substituted methyl furan group, an optionally substituted 3-ethyl indole group, and a lower alkyl group. Compositions containing pyrazolopyrimidine compounds and methods for using pyrazolopyrimidine compounds are described.

  吡唑吡咯嘧啶类化合物用于抑制异戊二烯生物合成，其化学式（I）或其药学上可接受的盐。在式（I）中，R1包括一个烷基基团，R2包括一个从可选取的苯甲基基团、可选取的苯乙基基团、可选取的乙醇基团、可选取的乙酸乙酯基团、可选取的甲基呋喃基团、可选取的3-乙基吲哚基团和较低烷基基团中选择的可选取的取代基团。描述了含有吡唑吡咯嘧啶类化合物的组合物和使用吡唑吡咯嘧啶类化合物的方法。